跳到正文
原文
NEJM· Cary O. HardingOregon Health and Science University, PortlandNicola LongoUniversity of California, Los Angeles, Los AngelesMarkey McNuttUniversity of Texas Southwestern Medical Center, DallasRani H. SinghEmory University, AtlantaAndreu ViaderGeorge VratsanosHaoling H. WengElaina JureckiFernanda Leal-PardinasJnana Therapeutics, BostonWei LiOtsuka Pharmaceutical Development and Commercialization, Rockville, MDGuissou DabiriJohn P. ThroupJnana Therapeutics, BostonAnia C. Muntaufor the JNT517-101 Trial Investigators Group*University Medical Center Hamburg–Eppendorf, Hamburg, Germany·· 20 天前精选AI 评分58

SLC6A19抑制剂Repinatrabit与苯丙酮尿症患者的苯丙氨酸水平

SLC6A19 Inhibitor Repinatrabit and Phenylalanine Levels in Phenylketonuria

AI 导读

NEJM刊出JNT517-101试验研究者的通讯文章,报告SLC6A19抑制剂Repinatrabit与苯丙酮尿症患者苯丙氨酸水平相关的结果,文章位于第395卷第17期1760至1763页。目前仅有摘要信息,具体数据未披露。

来源:NEJM · nejm.org